For example, ATR inhibitor AZD6738 sensitized BRCA2 mutant, BRCA2 reversion mutation, and BRCA1 wild-type ovarian cancer cells to olaparib more effectively than the CHK1 inhibitor MK8776 (271). This evidence concerns the gene BRCA2 and ovarian carcinoma.